The data indicate that all cases of primary CRC and CRCLM might be adaptable for CAR-T cell therapy targeting any of the three membrane-type protein cancer antigens, namely CLDN1, EphB4, and LAT1. This evidence concerns the gene EPHB4 and cancer.